Gilead Sciences is a global biopharma company with diverse portfolio and is known for its infectious disease drug portfolio.
- In Sep 2020, Gilead Sciences acquired worldwide rights to Jounce Therapeutics, Inc. (Nasdaq: JNCE), JTX-1811 program. JTX-1811 is a monoclonal antibody designed to target CCR8, a chemokine receptor, to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells. Under the terms, Jounce will lead development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop JTX-1811. Gilead paid $85 Mn in upfront payment and a $35 Mn in equity investment in Jounce Therapeutics. In addition, Jounce may receive up to an additional $685 Mn in future clinical, regulatory and commercial milestone payments. Jounce will also be eligible to receive royalties ranging from high single digit to mid-teens based upon worldwide sales.
- In Aug 2020, Gilead Sciences (Nasdaq: GILD) and Tango Therapeutics expanded their previous 2018 multi-year drug discovery collaboration using Tango’s proprietary CRISPR-enabled functional genomics target discovery platform to identify novel immune evasion targets number covered, from five to 15. Under the terms, Gilead paid $125 Mn in upfront and a $20 Mn equity investment in the company. In addition, Gilead will have the right to option up to 15 programs over the seven-year collaboration for up to $410 Mn per program in opt-in, extension and milestone payments. The collaboration excludes Tango’s lead programs, including the one which is expected to be in IND phase in 2021. Tango also retains the rights to identify targets outside the immune evasion space as it continues to build its wholly owned pipeline.
- In July 2020, Kronos Bio entered into an asset purchase agreement with Gilead Sciences, Inc. to acquire Gilead’s spleen tyrosine kinase (SYK) inhibitor portfolio. The portfolio includes the clinical stage compounds entospletinib, which has been evaluated in Phase 1 and Phase 2 clinical trials in oncology patients, and lanraplenib, which has been evaluated in Phase 2 clinical trials in patients with autoimmune diseases. Under the terms, Gilead received an upfront cash payment and a note convertible into Kronos equity, and will be eligible to receive regulatory and commercial milestones and royalties on future sales of products arising from the acquired programs.
- In May 2020, Gilead Sciences and Arcus Biosciences entered into a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s pipeline. Under the terms, Arcus received $375 Mn ($175 Mn cash upfront + $200 Mn in equity investment) from Gilead. Arcus is eligible to receive up to $1.225 billion in opt-in and milestone payments with respect to its current clinical product candidates. Gilead gained access to Arcus’s current and future investigational I/O products through the agreement. This includes immediate rights to zimberelimab/AB122, as well as the right to opt-in to all other current Arcus clinical candidates, which include AB154, AB928 and AB680, upon payment of an opt-in fee that ranges from $200 Mn to $275 Mn per program. If Gilead opts-in to the AB154 program, Arcus is eligible to receive up to $500 Mn in potential future U.S. regulatory approval milestones. Also, Gilead will receive the right to opt-in to all other programs that emerge from Arcus’s research portfolio over the next 10 years, upon payment of an opt-in fee of $150 Mn per program after Arcus’s delivery of a qualifying data package.
- In Apr 2020, Gilead Sciences, Kite (a Gilead Company) and oNKo-innate entered into a three-year cancer immunotherapy research collaboration to focused on natural killer (NK) cells. Under the terms, oNKo-innate to use its genome-wide screening techniques and proprietary technology platform to discover novel immune cell targets that enhance NK cell anti-tumor immunity and to create NK cell therapies. For Gilead, oNKo-innate will execute screens to identify and validate targets to seed internal Gilead immuno-oncology discovery programs. For Kite, oNKo-innate will create and evaluate NK constructs for Kite’s development of next-generation cell therapies. Financial terms remains undisclosed.
- In July 2019, Forty Seven (now part of Gilead Sciences) granted Ono Pharmaceutical, development, manufacture and commercialization rights for Forty Seven’s 5F9 (now Magrolimab), monoclonal antibody against CD47 for Japan, South Korea, Taiwan and the ASEAN countries. Forty Seven retains all rights to 5F9 in the rest of the world including the United States, Europe and China. Under the terms, Forty Seven received one-time upfront payment of approximately $15.8 Mn from Ono and is eligible to receive up to $104 Mn in form of future development and commercial milestones.
- In June 2019, Gilead and Nurix Therapeutics (NRIX: NASDAQ) sign collaboration to discover a pipeline of targeted protein degradation drugs in cancer and other challenging diseases, utilizing Nurix’s technology platform with Gilead is taking an option to license up to five drug candidates from the collaboration. Under the terms, Nurix will receive an upfront payment of $45 Mn and will be eligible to receive up to approx. $2.3 billion in total additional payments based on the successful completion of certain milestones.
- In Dec 2018, Gilead Sciences and Agenus Inc. entered into a partnership to develop and commercialize up to five novel immuno-oncology therapies. Under the terms, Agenus received $150 Mn in upfront payment and upto approx. $1.7 billion in potential future fees and milestones. Gilead acquired worldwide exclusive rights to AGEN1423, with an option to receive the exclusive option to license two additional programs: AGEN1223 and AGEN2373. Agenus will be responsible for developing the option programs up to the option decision points, at which time Gilead may acquire exclusive rights to the programs on option exercise.
- In Dec 2018, Gilead and Scholar Rock (NASDAQ:SRRK), entered into a strategic collaboration to discover and develop highly specific inhibitors of TGFβ activation for the treatment of fibrotic diseases. As per terms, Gilead has exclusive worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs. Scholar Rock is responsible for antibody discovery and preclinical research, after which, upon exercising the option for a program, Gilead will be responsible for the program’s preclinical and clinical development and commercialization. Scholar Rock received $80 Mn in upfront payments, ($50 Mn cash & $30 Mn in equity purchase) and is eligible to receive up to an additional $1,425 Mn in potential payments aggregated across all three programs based on the successful achievement of certain research, development, regulatory and commercialization milestones. Scholar Rock shall also receive royalties on sales of potential future products originating from the collaboration.
- In Aug 2018, Sierra Oncology acquired the drug candidate momelotinib from Gilead Sciences. Momelotinib has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis. Under the terms, Sierra paid Gilead a $3 million upfront fee for momelotinib and potential aggregate milestone payments of up to $195 Mn.
- In Dec 2014, Gilead Sciences, Inc. acquired the development and commercialization of ONO-4059 (now Tirabrutinib/ GS-4059), ONO’s oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of B-cell malignancies and other diseases, in all countries of the world outside of Japan, South Korea, Taiwan, China and the Association of Southeast Asian Nations (ASEAN) countries, where ONO retains development and commercialization rights. Financial details remains undisclosed.
- In 2014, Phenex Pharmaceuticals out license its most advanced novel drug, Cilofexor to Gilead Sciences, and is currently in Ph II clinical development.
- In Jan 2013, MacroGenics entered into a license agreement with Gilead Sciences for the development and commercialization of DART™ products directed at up to four undisclosed targets. Gilead has exclusive worldwide rights for three of the programs.
Page 2 of 3
